Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis

Liberal, Rodrigo; Grant, Charlotte R.; Sakkas, Lazaros I.; Bizzaro, Nicola; Bogdanos, Dimitrios P.

doi:10.1016/j.clinre.2013.04.005

Cited by 58 publications

(34 citation statements)

References 168 publications

(245 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antinuclear antibodies are detected by IIF in 30% to 50% of PBC patients. 5,6,8,9,36,37 Antinuclear antibodies detected by IIF using HEp-2 cells show various staining patterns, depending on the corresponding nuclear antigens (►Fig. 1; ►Table 1).…”

Section: Antinuclear Antibodiesmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Significance of Autoantibodies in Primary Biliary Cirrhosis

Nakamura

2014

Semin Liver Dis

View full text Add to dashboard Cite

Antimitochondrial, anti-gp210, anti-sp100, and anticentromere antibodies are specifically detected in primary biliary cirrhosis (PBC). In clinical practice, they are useful for the diagnosis of PBC or for evaluating disease severity, clinical phenotype, and long-term outcome. In the typical or classical form of PBC which shows slow progressive loss of small bile ducts with a parallel increase in liver fibrosis, anti-gp210 antibodies are a strong risk factor for progression to jaundice and hepatic failure, whereas the presence of anticentromere antibodies is a risk factor for progression to cirrhosis and portal hypertension. Of note, the autoimmune repertoire, which is established during the early stage of the disease process, can influence the clinical phenotype and the long-term prognosis of PBC. Because the natural course of PBC is being altered by treatment with ursodeoxycholic acid, the clinical significance of these PBC-specific autoantibodies awaits re-evaluation in various ethnicities.

show abstract

Section: Antinuclear Antibodiesmentioning

confidence: 99%

“…It is the site to which spindle fibers attach during cell division to pull sister chromatids apart. 9 Anticentromere antibodies, which were originally found in patients with systemic sclerosis (SSc), are found in a discrete speckled pattern of nuclear staining in HEp-2 cells (►Fig. 1E).…”

Section: Anticentromere Antibodiesmentioning

confidence: 99%

Clinical Significance of Autoantibodies in Primary Biliary Cirrhosis

Nakamura

2014

Semin Liver Dis

View full text Add to dashboard Cite

show abstract

“…The presence of anticentromere antibodies (ACA), a feature of systemic sclerosis, has been described in PBC without the coexistence of systemic sclerosis . In two different Asian cohorts an association was found between ACA and the occurrence of portal hypertension without the features of synthetic failure .…”

Section: Current Tools For Risk Stratificationmentioning

confidence: 99%

Precision medicine in primary biliary cholangitis

Ronca

Gerussi

Cristoferi

et al. 2019

J of Digest Diseases

View full text Add to dashboard Cite

For many years the one‐size‐fits‐all approach has been the only one available to manage patients affected by primary biliary cholangitis. The introduction of obeticholic acid in 2016 as a second‐line treatment, together with the creation and validation of several biochemically based scores to stratify the risk of progressive disease, has opened up the need to redefine clinical practice by changing the actual paradigm. The precision medicine initiative is a model of patient‐centered health care that aims to improve medicine based on genotypic and molecular characteristics that correlate to specific phenotypic, individual characteristics. In summary, the aim of the precision medicine is to define the right treatment for the right person at the right time. The availability of a second‐line disease‐modifying drug and new molecules in phase 2 or 3 trials makes this an exciting time for the precision medicine initiative in primary biliary cholangitis. In this review we describe the current risk stratification tools and we track a possible path towards the application of precision medicine in clinical daily life.

show abstract

“…Elevation of ALT worsened response was an observable risk factor for development to end-stage hepatic illness with persistent icterus[105]. Of PBC patients with ACAs positivity, 30% had serious bile duct damage and portal hypertension[106]. Therefore, the presence of ACAs is a risk factor for development to hepatic cirrhosis and portal-venous hypertension[101,105,106].…”

Section: Serological Featuresmentioning

confidence: 99%

“…Of PBC patients with ACAs positivity, 30% had serious bile duct damage and portal hypertension[106]. Therefore, the presence of ACAs is a risk factor for development to hepatic cirrhosis and portal-venous hypertension[101,105,106]. Biochemical response to UDCA therapy at two years, which is affected by the serum autoantibody status of ACAs, anti-gp210, and histological and morphometric variables at baseline, may predict long-term clinical results in PBC patients[105].…”

Section: Serological Featuresmentioning

confidence: 99%

Recent advances in the diagnosis and treatment of primary biliary cholangitis

Huang¹

2016

WJH

View full text Add to dashboard Cite

Primary biliary cholangitis (PBC), formerly referred to as primary biliary cirrhosis, is an infrequent progressive intrahepatic cholestatic autoimmune illness that can evolve into hepatic fibrosis, hepatic cirrhosis, hepatic failure, and, in some cases, hepatocellular carcinoma. The disease itself is characterized by T-lymphocyte-mediated chronic non-suppurative destructive cholangitis and elevated serum levels of extremely specific anti-mitochondrial autoantibodies (AMAs). In this article, we will not only review epidemiology, risk factors, natural history, predictive scores, radiologic approaches (e.g., acoustic radiation force impulse imaging, vibration controlled transient elastography, and magnetic resonance elastography), clinical features, serological characteristics covering biochemical markers, immunoglobulins, infections markers, biomarkers, predictive fibrosis marker, specific antibodies (including AMAs such as AMA-M2), anti-nuclear autoantibodies [such as anti-multiple nuclear dot autoantibodies (anti-sp100, PML, NDP52, anti-sp140), anti-rim-like/membranous anti-nuclear autoantibodies (anti-gp210, anti-p62), anti-centromere autoantibodies, and some of the novel autoantibodies], histopathological characteristics of PBC, diagnostic advances, and anti-diastole of PBC. Furthermore, this review emphasizes the recent advances in research of PBC in terms of therapies, including ursodeoxycholic acid, budesonide, methotrexate, obeticholic acid, cyclosporine A, fibrates such as bezafibrate and fenofibrate, rituximab, mesenchymal stem cells transplant, and hepatic transplant. Currently, hepatic transplant remains the only optimal choice with acknowledged treatment efficiency for end-stage PBC patients.

show abstract

Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis

Cited by 58 publications

References 168 publications

Clinical Significance of Autoantibodies in Primary Biliary Cirrhosis

Clinical Significance of Autoantibodies in Primary Biliary Cirrhosis

Precision medicine in primary biliary cholangitis

Recent advances in the diagnosis and treatment of primary biliary cholangitis

Contact Info

Product

Resources

About